📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. (2023)

First Author: Fisher A

Attributed to: Chronic Lymphocytic Leukaemia: uncovering immunity during first-line treatment funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fonc.2023.1130617

PubMed Identifier: 36910619

Publication URI: http://europepmc.org/abstract/MED/36910619

Type: Journal Article/Review

Volume: 13

Parent Publication: Frontiers in oncology

ISSN: 2234-943X